Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: GlobalData
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals announces publication of pivotal data from SIVEXTRO (tedizolid phosphate) ESTABLISH-2 Clinical Trial in The Lancet Infectious Diseases

Friday, 6 Jun 2014 09:00am EDT 

Cubist Pharmaceuticals Inc:Says The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a Phase 3 clinical trial of investigational antibiotic SIVEXTRO (tedizolid phosphate).Developed for treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI). 

Company Quote

0.9 +0.92%
19 Dec 2014